PV Bulletin

GE HealthCare Infant Resuscitation System Air-Oxygen Blender Issue

FDA issued an early alert regarding a potentially high-risk issue with GE HealthCare Infant Resuscitation Systems where the air-oxygen blender knob shaft can loosen, affecting delivered oxygen concentration.

PV Impact Brief

Urgency: HighConfidence: high

What changed

FDA issued an Early Alert notifying the public of a potentially high-risk device issue with GE HealthCare Infant Resuscitation Systems, recommending affected devices be corrected prior to continued use.

Why it matters

The issue could lead to hypoxia or hyperoxia in infant patients if the device delivers incorrect oxygen concentration.

Action needed

Identify and remove affected devices from use until corrected; if use is necessary, follow additional precautions provided in the GE HealthCare customer letter.

Relevant for
Regulatory Intelligence LeadSignal Management Lead
Processes impacted
Signal ManagementLabeling
Owner

Regulatory Intelligence Lead

Review cadence

as needed until resolved

Regulatory action details

Action type
Early Alert
Publication date
2026-06-05
Safety issue
The FDA issued an early alert regarding an issue with the Infant Resuscitation System from GE HealthCare.

Affected products

  • Infant Resuscitation System
    GE HealthCare

PV internal implications

Follow the instructions in the alert.

View regulator source

Evidence and confidence

Confidence: highSource updated: Jun 5, 2026

Full briefing

Practical implication

Identify and remove affected devices from use until corrected; if use is necessary, follow additional precautions provided in the GE HealthCare customer letter.

FDA issued an early alert on June 5, 2026, concerning GE HealthCare Infant Resuscitation Systems and Warmers with M1091607-R blender. The knob shaft may loosen, causing oxygen concentration mismatch and potential hypoxia or hyperoxia. No serious injuries or deaths reported as of May 20, 2026.

What changed: FDA issued an Early Alert notifying the public of a potentially high-risk device issue with GE HealthCare Infant Resuscitation Systems, recommending affected devices be corrected prior to continued use.

Why it matters: The issue could lead to hypoxia or hyperoxia in infant patients if the device delivers incorrect oxygen concentration.

Practical implication: Identify and remove affected devices from use until corrected; if use is necessary, follow additional precautions provided in the GE HealthCare customer letter.

View original source

Published from the Firecrawl agent regulatory extraction pipeline.

Related updates for your role

publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Urgency: High

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicMedicines and Healthcare products Regulatory Agency (MHRA) · United Kingdom · Updated May 23, 2026

MHRA confirms UK clinical trial safety reporting guidance is effective

Urgency: High

Safety lead to: (1) perform a UK-clinical-trial safety reporting gap assessment against MHRA’s effective guidance sections (MedDRA coding; AE/SAE; RSI governance; SUSARs; annual safety reporting; USMs; serious breaches; temporary suspension), (2) update controlled SOPs/WIs and training records to reflect “effective” status as of 28 Apr 2026, and (3) document deviations/gaps and open CAPA where needed for ongoing UK trials and new submissions.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact4 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Guidance
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Urgency: High

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Agenda
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward